Furthermore, serum Her2 levels were significantly higher in prostate cancer patients than in control subjects without cancer and serum Her2 levels were significantly higher in patients with metastatic disease than those without metastatic disease [4]. This evidence concerns the gene ERBB2 and metastatic neoplasm.